Kaléo Announces License Agreement with Amgen for Auto-Injector Technology

Glen Allen, VA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Kaléo today announced that it has entered into a confidential license agreement with Amgen Inc. Under the terms of the agreement, Amgen obtained a license to certain of Kaléo's patented technology on auto-injectors. This agreement reflects Kaléo's innovative contribution to drug-device technologies and longstanding leadership in advancing patient-centric auto-injector solutions. Financial and other terms of the agreement were not disclosed.

About Kaléo

Kaléo is a pharmaceutical company and global leader in drug-delivery device technology and auto-injector innovation, providing millions of patients with security and peace of mind. Our patented Aerio™ platform, with unmatched capabilities and human factors engineering, powers our portfolio of auto-injector products, as well as products under development for third parties. Visit www.kaleo.com.

###

CC-US-0234

Carrie Siragusa 
Kaléo
[email protected]

You May Also Be Interested In

• Wix.com Ltd. Notice of September 22, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
• CHARBONE's Phase 1B Takes a Major Step Forward as Electrolyzer Arrives at Sorel-Tracy
• Hub Group, Inc. Securities Fraud Class Action Result of Erroneous Financial Statements and approximately 31% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC